[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"secondary-progressive-multiple-sclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:secondary-progressive-multiple-sclerosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,75,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100615931","phase-3-a-study-of-orelabrutinib-in-patients-with-secondary-progressive-multiple-sclerosis-100615931",false,"NCT07299019","A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis","A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-active Secondary Progressive Multiple Sclerosis","Inclusion Criteria:\n\n1. 18 to 60 years of age, inclusive, at the time of signing the informed consent.\n2. Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria\n3. Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013\n4. Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).\n5. Absence of clinical relapses for at least 24 months.\n\nExclusion Criteria:\n\n1. The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria\n2. Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.\n3. History or current diagnosis of other neurological disorders that may mimic MS\n4. History or current diagnosis of progressive multifocal leukoencephalopathy\n5. Active, clinically significant viral, bacterial, or fungal infection\n6. History of any other significant active medical condition\n7. History of suicidal behavior within 6 months prior to Screening\n8. Any prior history of malignancy\n9. Patients on anticoagulation, or antiplatelet therapy\n10. Patients took strong\u002Fmoderate CYP3A inhibitors or strong\u002Fmoderate CYP3A inducers within 14 days\n11. Clinically significant laboratory abnormalities at Screening.\n12. Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening\n13. History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.","ALL","18 Years","60 Years",{"count":20,"type":21},990,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.",[27],"Secondary Progressive Multiple Sclerosis","RECRUITING","2026-06-25",{"date":31,"type":32},"2026-06-30","ACTUAL",{"date":34,"type":32},"2026-03-23",{"date":36,"type":21},"2030-07",{"name":38,"class":39},"Zenas BioPharma (USA), LLC","INDUSTRY",13,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100366158","phase-3-best-available-therapy-versus-autologous-hematopoietic-stem-cell-transplant-for-multiple-sclerosis-beat-ms-100366158","NCT04047628","Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)","BEAT-MS","Inclusion Criteria:\n\n1. Age 18 to 55 years, inclusive, at the time of the screening Visit -2.\n2. Diagnosis of MS according to the 2017 McDonald Criteria139.\n3. EDSS ≤ 6.0 at the time of randomization (Day 0).\n4. T2 abnormalities on brain MRI that fulfill the 2017 McDonald MRI criteria for dissemination in space139. A detailed MRI report or MRI images must be available for review by the site neurology investigator.\n5. Highly active treatment-resistant relapsing MS, defined as ≥ 2 episodes of disease activity in the 36 months prior to the screening visit (Visit -2). The two disease activity episodes will be a clinical MS relapse or MRI evidence of MS disease activity and must meet all the criteria described below:\n\n   1. At least one episode of disease activity must occur following ≥ 1 month of treatment with one of the following: (i) an oral DMT approved by the FDA for the treatment of relapsing MS, or (ii) a monoclonal antibody approved by the FDA for the treatment of relapsing MS, or (iii) rituximab. Qualifying DMTs include: dimethyl fumarate, diroximel fumarate, monomethyl fumarate, teriflunomide, cladribine, daclizumab, ponesimod, siponimod, ozanimod, fingolimod, rituximab, ocrelizumab, natalizumab, alemtuzumab, ublituximab, and ofatumumab, and\n   2. At least one episode of disease activity must have occurred within the 12 months prior to the screening visit (Visit -2), and\n   3. At least one episode of disease activity must be a clinical MS relapse (see item c.i. below). The other episode(s) must occur at least one month before or after the onset of the clinical MS relapse, and must be either another clinical MS relapse or MRI evidence of disease activity (see item c.ii. below):\n\n   i. Clinical MS relapse must be confirmed by a neurologist's assessment and documented contemporaneously in the medical record. If the clinical MS relapse is not documented in the medical record, it must be approved by the study adjudication committee (see Section 3.5), and ii. MRI evidence of disease activity must include ≥ 1 unique active lesion on one or more brain or spinal cord MRIs. Detailed MRI reports or MRI images must be available for review by the site neurology investigator. A unique active lesion is defined as either of the following:\n\n1\\. A gadolinium-enhancing lesion, or 2. A new non-enhancing T2 lesion compared to a reference scan obtained not more than 36 months prior to the screening visit (Visit -2).\n\n6\\. Candidacy for treatment with at least one of the following high efficacy BAT DMTs: cladribine, natalizumab, alemtuzumab, ocrelizumab, ofatumumab, ublituximab and rituximab. Candidacy for treatment for each BAT DMT is defined as meeting all of the following:\n\n1. No prior disease activity episode, as defined in Inclusion Criterion #5, with the candidate BAT DMT, and\n2. No contraindication to the candidate BAT DMT, and\n3. No treatment with the candidate BAT DMT in the 12 months prior to screening.\n\n   7\\. Completion of COVID-19 vaccination series, according to the current Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations, ≥ 14 days prior to randomization (Day 0).\n\n   8\\. Positive for VZV antibodies, or completion of at least one dose of the varicella zoster glycoprotein E (gE) Shingrix vaccine at least 4 weeks prior to randomization (Day 0).\n\n   9\\. Insurance approval for MS treatment with at least one candidate BAT DMT (see Inclusion Criterion #6).\n\n   10\\. Ability to comply with study procedures and provide informed consent, in the opinion of the investigator.\n\n   11\\. Females of childbearing potential (defined in Section 5.4.3.1) and males with female partners of childbearing potential are required to adhere to the contraception provisions of Section 5.4.3.1.\n\n   12\\. For participants who use medicinal or recreational marijuana, willingness to substitute MARINOL® if randomized to AHSCT (Section 5.4.2.6).\n\nExclusion Criteria:\n\n1. Diagnosis of primary progressive MS according to the 2017 McDonald criteria.\n2. History of neuromyelitis optica spectrum disorder or MOG antibody disease.\n3. Prior treatment with an investigational agent within 3 months or 5 half-lives, whichever is longer. Agents authorized by the FDA for prevention or treatment of COVID-19 are not considered investigational.\n4. Either of the following within one month prior to randomization (Day 0):\n\n   1. Onset of acute MS relapse, or\n   2. Treatment with intravenous methylprednisolone 1000 mg\u002Fday for 3 days or equivalent.\n5. Initiation of any BAT DMT (see Section 5.2.1) between Visit -2 and randomization (Day 0).\n6. Brain MRI or cerebrospinal fluid (CSF) examination indicating a diagnosis of progressive multifocal leukoencephalopathy (PML).\n7. History of cytopenia consistent with the diagnosis of myelodysplastic syndrome (MDS).\n8. Presence of unexplained cytopenia, polycythemia, thrombocythemia or leukocytosis.\n9. History of sickle cell anemia or other hemoglobinopathy.\n10. Evidence of past or current hepatitis B or hepatitis C infection, including treated hepatitis B or hepatitis C. Hepatitis B surface antibody following hepatitis B immunization is not considered to be evidence of past infection.\n11. Presence or history of mild to severe cirrhosis.\n12. Hepatic disease with the presence of either of the following:\n\n    1. Total bilirubin ≥ 1.5 times the upper limit of normal (ULN) or total bilirubin ≥ 3.0 times the ULN in the presence of Gilbert's syndrome, or\n    2. Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 2.0 times the ULN.\n13. Positive COVID-19 PCR test, or alternative nucleic acid amplification test (NAAT) per institutional standards, within 14 days prior to randomization (Day 0).\n14. Evidence of HIV infection.\n15. Positive QuantiFERON - TB Gold,TB Gold Plus, or T-SPOT®.TB test results. PPD tuberculin test may be substituted for QuantiFERON - TB Gold, TB Gold Plus, or T-SPOT®.TB test.\n16. Active viral, bacterial, endoparasitic, or opportunistic infections.\n17. Active invasive fungal infection.\n18. Hospitalization for treatment of infections or parenteral (IV or IM) antibacterials, antivirals, antifungals, or antiparasitic agents within the 30 days prior to randomization (Day 0) unless clearance is obtained from an Infectious Disease specialist.\n19. Receipt of live or live-attenuated vaccines within 6 weeks of randomization (Day 0).\n20. Presence or history of clinically significant cardiac disease including: a. Arrhythmia requiring treatment with any antiarrhythmia therapy, with the exception of low dose beta blocker for intermittent premature ventricular contractions.\n\n    b. Coronary artery disease with a documented diagnosis of either: i. Chronic exertional angina, or ii. Signs or symptoms of congestive heart failure. c. Evidence of heart valve disease, including any of the following: i. Moderate to severe valve stenosis or insufficiency, or ii. Symptomatic mitral valve prolapse, or iii. Presence of prosthetic mitral or aortic valve.\n21. Left ventricular ejection fraction (LVEF) \\\u003C 50%.\n22. Impaired renal function defined as eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m2, according to the CKD-EPI formula144.\n23. Forced expiratory volume in one second (FEV1) \\\u003C 70% predicted (no bronchodilator).\n24. Diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for Hgb) \\\u003C 70% predicted.\n25. Poorly controlled diabetes mellitus, defined as HbA1c \\> 8%.\n26. History of malignancy, except adequately treated localized basal cell or squamous skin cancer, or carcinoma in situ of the cervix. Malignancies for which the participant is judged to be cured will be considered on an individual basis by the study adjudication committee (see Section 3.5).\n27. Presence or history of any moderate to severe rheumatologic autoimmune disease requiring treatment, including but not limited to the following: systemic lupus erythematous, systemic sclerosis, rheumatoid arthritis, Sjogren's syndrome, polymyositis, dermatomyositis, mixed connective tissue disease, polymyalgia rheumatica, polychondritis, sarcoidosis, vasculitis syndromes, or unspecified collagen vascular disease.\n28. Presence of active peptic ulcer disease, defined as endoscopic or radiologic diagnosis of gastric or duodenal ulcer.\n29. Prior history of AHSCT.\n30. Prior history of solid organ transplantation.\n31. Positive pregnancy test or breastfeeding.\n32. Failure to willingly accept or comprehend irreversible sterility as a side effect of therapy.\n33. Psychiatric illness, mental deficiency, or cognitive dysfunction severe enough to interfere with compliance or informed consent.\n34. History of hypersensitivity to rabbit or Escherichia coli-derived proteins.\n35. Any metallic material or electronic device in the body, or other condition that precludes the participant from undergoing MRI with gadolinium administration, as determined by the site radiologist.\n36. Presence or history of ischemic cerebrovascular disorders, including but not limited to transient ischemic attack, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism, or cerebral hemorrhage.\n37. Presence or history of other neurological disorders, including but not limited to CNS or spinal cord tumor; metabolic or infectious cause of myelopathy; genetically-inherited progressive CNS disorder; CNS sarcoidosis; or systemic autoimmune disorders potentially causing progressive neurologic disease or affecting ability to perform the study assessments.\n38. Presence of any medical comorbidity that the investigator determines will significantly increase the risk of treatment mortality.\n39. Presence of any other concomitant medical condition that the investigator deems incompatible with trial participation.","55 Years",{"count":51,"type":21},156,[24],"This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.\n\nAll participants will be followed for 72 months after randomization (Day 0, Visit 0).",[55,56,27],"Relapsing Multiple Sclerosis","Relapsing Remitting Multiple Sclerosis",[58,59,60,61,62,63],"Treatment-Resistant Relapsing Multiple Sclerosis (MS)","Autologous Hematopoietic Stem Cell Transplantation (AHSCT)","Autologous Peripheral Blood Stem Cells (PBMCs) Graft","Best Available Therapy (BAT)","Disease-Modifying Therapy (DMT)","BAT DMT","2026-01-02",{"date":66,"type":32},"2026-01-06",{"date":68,"type":32},"2019-12-19",{"date":70,"type":21},"2029-10",{"name":72,"class":73},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",22,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100345876","phase-1-sizomus-safety-of-ixazomib-targeting-plasma-cells-in-multiple-sclerosis-100345876","NCT03783416","SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis","Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial.","SIZOMUS","Inclusion Criteria:\n\n\\- Each participant must meet all of the following inclusion criteria to be enrolled in the study:\n\n1. Male and female patients 18 to 65 years old at screening\n2. Must have a diagnosis of MS, and:\n\n   * Patients with RRMS must be on DMT\n   * Patients with progressive MS must not be on DMT\n3. Participants with RRMS must be on stable DMT (i.e. must not have had a relapse within 1 month prior to the screening visit). Patients on tecfidera, cladribine, ocrelizumab, alemtuzumab, fingolimod or natalizumab must be enrolled with caution, at Chief Investigator's (CI) discretion because of the lymphopenia caused by these drugs and the risk of thrombocytopenia in 1-2 % of people after alemtuzumab\n4. OCB positive CSF either from a previous CSF analysis or from the screening CSF analysis\n5. Able and willing to give written informed consent and comply with protocol requirements with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.\n6. Agree to the use of effective contraception as follows:\n\n   Female patients must:\n   * Be postmenopausal for at least 1 year before the screening visit (postmenopausal status confirmed by serum Follicle Stimulating Hormone (FSH) and oestrogen levels at screening or from a historical sample), OR\n   * Surgically sterile, OR\n   * If they are of childbearing potential, must agree to practice two effective methods of contraception concurrently from the time of signing the informed consent form until 90 days after the last dose of study drug, OR\n   * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence e.g. calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception\n\n   Male patients must:\n   * Even if surgically sterilized (post-vasectomy with documentation of azoospermia), agree to practice effective barrier contraception during the entire study treatment period and through to 90 days after the last dose of study drug, OR\n   * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence e.g. calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception\n7. Clinical laboratory values:\n\n   1. Absolute neutrophil count (ANC) ≥ 1 x 109\u002FL\n   2. Platelet count ≥ 100 x 109\u002FL\n   3. Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN)\n   4. Alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) ≤ 3 × ULN.\n   5. Calculated creatinine clearance ≥ 30 mL\u002Fmin\n\nExclusion Criteria:\n\n* Participants meeting any of the following exclusion criteria are not to be enrolled in the study:\n\n  1. EDSS \\> 8.5 at screening\n  2. MS relapse within 1 month prior to screening\n  3. Female patients who are lactating or have a positive serum pregnancy test at screening\n  4. Major surgery within 14 days before baseline\n  5. Any clinically relevant malignancy or infection, as per CI\u002FPI (or delegate) decision, including a possible diagnosis of multiple myeloma: raised erythrocyte sedimentation rate (ESR) and positive urine Bence Jones protein at screening\n  6. Infection requiring systemic (intravenous) antibiotic therapy or other serious infection within 14 days before study enrolment. Urinary tract infections (UTIs) will be treated prior to baseline and may delay baseline\n  7. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within 6 months of screening\n  8. Systemic treatment, within 14 days before the first dose of ixazomib, with strong Cytochrome P450 Isoform 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's Wort\n  9. History of active hepatitis B or C virus infection, or human immunodeficiency virus (HIV) positive or positive Tuberculin (TB) ELISPOT. If there is positive TB ELISPOT and the TB team decides to treat as latent TB, participants can be reassessed for inclusion after treatment\n  10. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol\n  11. Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing\n  12. Diagnosed or treated for malignancy within 2 years before study enrolment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection\n  13. Patient has ≥ Grade 3 peripheral neuropathy, or Grade 2 with pain on clinical examination during the screening period\n  14. Participation in other clinical trials involving investigational (unlicensed) medicinal products, licensed medicinal products or alternative medicinal therapies, within 30 days of screening and throughout the duration of this trial. Participation in non-interventional, questionnaire or observational studies whilst enrolled in this study is permitted.\n  15. Patients that have previously been treated with ixazomib or participated in a study with ixazomib whether treated with ixazomib or placebo\n  16. Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent\n  17. Any pre-existing central nervous system disease or involvement other than MS\n  18. History of uncontrolled drug or alcohol abuse within 6 months prior to screening.","65 Years",{"count":85,"type":21},72,[87],"PHASE1","The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.",[56,90,27],"Primary Progressive Multiple Sclerosis","2025-09-01",{"date":93,"type":32},"2025-09-04",{"date":95,"type":32},"2020-06-15",{"date":97,"type":21},"2026-07-31",{"name":99,"class":100},"Queen Mary University of London","OTHER",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":101},"100584291","cladribine-tablets-as-an-exit-therapy-strategy-100584291","NCT06887426","Cladribine Tablets as an Exit Therapy Strategy","Cladribine Tablets as an Exit Therapy Strategy: Alternative to Continuing Treatment and Plain Treatment Discontinuation in Ageing Stable RMS Patients","CLADREXIT","Inclusion Criteria:\n\n* Patient ≥45-year-old with RRMS\n* Disease duration ≥10 years\n* No evidence of disease activity ≥5 years under DMT\n* EDSS score between 0 and 6.0 included\n\nExclusion Criteria:\n\n* Progressive form of MS\n* Patients without DMT\n* EDSS score ≥6.5","45 Years",{"count":112,"type":21},450,"OBSERVATIONAL","The objective of the study is to evaluate the effectiveness of CladT, in terms of disease stability and safety, as the last treatment option in ageing MS patients vs treatment continuation and discontinuation This observational study will use database from local cohorts (from France, Belgium, Switzerland). Patients included must meet the inclusion criteria: RRMS diagnosis for more than 10 years without secondary progression, no evidence of disease activity (no relapse, no new MRI lesion, no EDSS progression) for more than 5 years under a DMT, age≥ 45-year-old.\n\nAnalyses will be using dynamic propensity score to match patients who stopped treatment with patients who had the same probability of continuing \u002F stopping current treatments but took CladT as exit therapy. Patients with a minimum of 24 months follow up will be included.\n\nThe investigators will ensure that CladT provide disease stability compared to treatment continuation \u002F discontinuation in ageing MS patients by measuring:\n\n* the percentage of patients free of relapse, and time to first relapse, defined as the appearance, recurrence, or aggravation of neurological symptoms for a period of at least 24 hours without fever.\n* the percentage of patients free of EDSS progression confirmed for at least 6 months and until the end of patient follow up.\n* the percentage of patients free of MRI activity, defined as new or enlarged T2 lesions compared with the previous brain MRI scan or gadolinium enhancing T1 lesions.",[116,56,27],"Multiple Sclerosis","NOT_YET_RECRUITING","2025-05-27",{"date":120,"type":32},"2025-06-02",{"date":122,"type":21},"2025-06",{"date":124,"type":21},"2025-12",{"name":126,"class":100},"University Hospital, Strasbourg, France"]